Banks have reportedly suggested a $120bn valuation for Uber's IPO, while Lyft has chosen JP Morgan to lead an offering that could value it at more than $15bn.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang Insurance are in line for exits as Innovent Biologics gears up for an initial public offering sized at $400m to $500m.

The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.

Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.

The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.

GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.

Cellular therapy developer Gamida Cell, which counts Novartis as its largest investor, has filed for a $69m initial public offering.